Deals > All

East Germany North Germany South Germany West Germany Austria Germany Switzerland [ # 12 & 35 ]

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4802 | Ordered by Date (descending)
1 2 3 ... 47 48 49

Deal: Collaboration or Financing	Date
Evotec–Adapsyn Biotechnology: drug discovery, 202209– strategic collab €na providing Evotec with accesss to drug-like small molecules for screening	2022-09-21
EFOS (SI)–ECBF: investment, 202209 financing round Series B totalling €10m incl lead investor European Circular Bioeconomy Fund	2022-09-20
EFOS (SI)–SEVERAL: investment, 202209 financing round Series B €10m led by ECBF	2022-09-20
Nuvisan–Gates Foundation: grant, 202209– grant $9.6m for RnD on non-hormonal contraceptive medicines at Nuvisan ICB GmbH	2022-09-20
Nilogen Oncosystems–Scailyte: personalised medicine, 202209 collab existent developm omics platform for analyzing tumour tissues for I-O developm	2022-09-19
Scailyte–Mirabaud: investment, 202209 financing round Series A totalling CHF6m incl new investor Mirabaud bank	2022-09-19
Scailyte–OTHER: investment, 202209 financing round Series A totalling CHF6m incl Swiss family office as new investor	2022-09-19
Scailyte–SEVERAL: investment, 202209 financing round Series A CHF6m with Swiss family office + Mirabaud bank + existing investors	2022-09-19
Scailyte–Swisscom: investment, 202209 financing round Series A totalling CHF6m incl existing investor Swisscom Ventures	2022-09-19
Aignostics–Berlin (govt): investment, 202209 financing round Series A totalling €14m incl existing + co-investor VC Fonds Technologie (IBB Ventures)	2022-09-15
Aignostics–Boehringer: investment, 202209 financing round Series A totalling €14m incl existing + co-investor BIVF	2022-09-15
Aignostics–Carma Fund: investment, 202209 financing round Series A totalling €14m incl new + co-investor Carma Fund	2022-09-15
Aignostics–High-Tech Gründerfonds: investment, 202209 financing round Series A totalling €14m incl existing + co-investor HTGF	2022-09-15
Aignostics–MC Services: public relations, 202209 service existent by MC Services	2022-09-15
Aignostics–SEVERAL: investment, 202209 financing round Series A €14m led by Wellington Partners	2022-09-15
Aignostics–Wellington Partners: investment, 202209 financing round Series A totalling €14m incl new + lead investor Wellington Partners	2022-09-15
Capstan Therapeutics–SEVERAL: investment, 202209c recently closed financing round Series A 102$m led by Pfizer Ventures	2022-09-14
faCellitate–Arve Capital: investment, 202209 seed financing round totalling €3.7m incl co-investor Arve Capital (Sanner Family Office)	2022-09-07
faCellitate–BASF: investment, 202209 seed financing round totalling €3.7m incl co-investor Chemovator	2022-09-07
faCellitate–High-Tech Gründerfonds: investment, 202209 seed financing round totalling €3.7m incl co-lead investor HTGF	2022-09-07
faCellitate–ROI Verwaltungsgesellschaft: investment, 202209 seed financing round totalling €3.7m incl co-investor ROI (Roland Oetker)	2022-09-07
faCellitate–R³ Consulting: investment, 202209 seed financing round totalling €3.7m incl co-investor R3 Consulting und Investment GmbH	2022-09-07
faCellitate–Sarstedt: investment, 202209 seed financing round totalling €3.7m incl co-lead investor Sarstedt	2022-09-07
faCellitate–SEVERAL: investment, 202209 seed financing round €3.7m led by Sarstedt + HTGF	2022-09-07
Indivumed–CellPhenomics: drug target research, 202209– collab to develop platform for cancer drug target discovery + validation	2022-09-07
QLi5 Therapeutics–SEVERAL: investment, 202209 financing round Series A €10m incl SV Investemnt + KHAN + Atinum Investment + DAOL Investment	2022-09-07
Roche–PhoreMost: drug target discovery services, 202209– collab €na using Siteseeker platform on pathways nominated by Roche	2022-09-06
2bind–Dynamic Biosensors: switchSENSE technology, 202209– collab technology-service with 2bind using HeliX biosensor system as certified beta customer	2022-09-01
C-mo Medical Solutions–Boehringer: investment, 202209 seed financing round totalling €4.1m incl lead investor BIVF	2022-09-01
C-mo Medical Solutions–High-Tech Gründerfonds: investment, 202209 seed financing round totalling €4.1m incl co-investor HTGF	2022-09-01
C-mo Medical Solutions–SEVERAL: investment, 202209 seed financing round €4.1m led by BIVF	2022-09-01
Central Glass–Evotec: investment, 202208–202211 acquisition of Central Glass Germany GmbH for € 1 by Evotec	2022-08-25
Novartis–SEVERAL: investment, 202208– spin-off of Sandoz division to be listed on SIX with ADR programme ANNOUNCED	2022-08-25
ChemDiv–Schaffhausen Institute of Technology: drug discovery, 202208– collab strategic establishment of dedicated research group at Jacobs Univ	2022-08-11
United Kingdom (govt)–Carl Zeiss: microscopy, 202208– collab of MDC + Zeiss for advanced microscopy solutions for drug discovery + early development	2022-08-11
Vector BioPharma–Versant Ventures: investment, 202208 company emerges with $30m Series A commitment from Versant Ventures	2022-08-10
Albumedix–Eversheds Sutherland: legal services, 202208 supply service legal counsel to Albumedix with regard to £415m acquisition by Sartorius	2022-08-08
Albumedix–Sartorius: investment, 202208– acquisition £415m 100% of Albumedix by Sartorius Stedim Biotech ANNOUNCED	2022-08-08
Albumedix–William Blair: financial services, 202208 supply service financial advisor to Albumedix with regard to £415m acquisition by Sartorius	2022-08-08
Atlas Antibodies–Genovis: MS-based analysis of biopharmaceuticals, 202208– supply service LC-MS analytics of recombinant CHO-antibodies to Evitria	2022-08-08
Sartorius–Milbank: legal services, 202208 supply service legal counsel to Sartorius with regard to £415m acquisition of Albumedix	2022-08-08
Genmab–BioNTech: cancer immunotherapy, 202208– collab expansion 50/50 cost + profit sharing developm + commercn monospeific antibodies using HexaBody	2022-08-05
ChemoCentryx–Amgen: investment, 202208– acquisition $3.7b at $52/share ANNOUNCED	2022-08-04
Biosynth Carbosynth–Eucodis Bioscience: industrial enzymes, 202208 collab existent for many years	2022-08-02
Eucodis Bioscience–Biosynth Carbosynth: investment, 202208 acquisition of Eucodis by Biosynth Carbosynth	2022-08-02
Haermonics–SEVERAL: investment, 202208 financing round Series C €4.3m led by BOM + Demcon + Stepping Stone/NLC	2022-08-02
Mementor–ResMed: investment, 202208 acquisition €na of Mementor DE GmbH by ResMed	2022-08-01
Cleerly–Novartis: investment, 202207 financing round Series C totalling $223m incl new + co-investor Novartis	2022-07-28
Cleerly–SEVERAL: investment, 202207 financing round Series C $223m led by T Rowe Price + Fidelity	2022-07-28
NeoSphere Biotechnologies–SEVERAL: investment, 202207 financing round Series A	2022-07-25
Dermagnostix–EU (govt): grant, 202207c EIC accelerator grant €2.5m	2022-07-22
Dermagnostix–SEVERAL: investment, 202207 seed financing round extension €4.6m from existing + new investors	2022-07-22
Delfi Diagnostics–Allianz: investment, 202207 financing round Series B totalling $225m incl existing + co-investor AV8 Ventures	2022-07-18
Delfi Diagnostics–SEVERAL: investment, 202207 financing round Series B $225m led by DFJ Growth	2022-07-18
Forty51 Ventures–Fischli Group: investment, 202207 first closing totalling $43m of Forty51 Ventures I fund incl co-lead investor Fischli Family	2022-07-18
Forty51 Ventures–OTHER: investment, 202207 first closing totalling $43m of Forty51 Ventures I fund incl biotech entrepreneures + private individuals	2022-07-18
Forty51 Ventures–SEVERAL: investment, 202207 first $43m closing of Forty51 Ventures I fund	2022-07-18
Forty51 Ventures–Stable Asset Management: investment, 202207 first closing totalling $43m of Forty51 Ventures I fund incl co-lead investor SAM	2022-07-18
SHS Capital–EU (govt): investment, 202207 first closing totalling over €220m of SHS VI fund incl investor EIF	2022-07-18
SHS Capital–Helsana HealthInvest: investment, 202207 first closing totalling over €220m of SHS VI fund incl investor Helsana HealthInvest	2022-07-18
SHS Capital–LBBW: investment, 202207 first closing totalling over €220m of SHS VI fund incl investor L-Bank Baden-Württemberg	2022-07-18
SHS Capital–OTHER: investment, 202207 first closing totalling over €220m of SHS VI fund incl larger family offices	2022-07-18
SHS Capital–OTHER: investment, 202207 first closing totalling over €220m of SHS VI fund incl SHS investment team itself	2022-07-18
SHS Capital–Realdania: investment, 202207 first closing totalling over €220m of SHS VI fund incl investor Realdania Foundation	2022-07-18
SHS Capital–SEVERAL: investment, 202207 first closing at over €220m of SHS VI fund with EIF + Realdania + Helsana HealthInvest + LBBW et al.	2022-07-18
Agomab Therapeutics–OTHER: investment, 202207 financing round Series B extension totalling $40.5m incl existing-investors	2022-07-13
Agomab Therapeutics–SEVERAL: investment, 202207 financing round Series B extension $40.5m led by Pfizer bringing total Series B to $114m	2022-07-13
Corat Therapeutics–Germany (govt): grant, 202207– up to €38.7m funding from BMBF for pivotal trial of Covid-19 drug candidate COR-101	2022-07-13
Mosanna Therapeutics–Forty51 Ventures: investment, 202207 seed financing round incl lead investor + co-founder Forty51 Ventures	2022-07-13
Mosanna Therapeutics–SEVERAL: investment, 202207 seed financing round led by Forty51 Ventures	2022-07-13
Swedish Orphan Biovitrum–ADC Therapeutics: loncastuximab tesirine-lpyl, 202207– license excl $55m upfront + $710m milestones outside US+China+SG+JP	2022-07-08
Biosyntia–ECBF: investment, 202207 financing round Series B totalling €11.5m incl new + lead investor ECBF	2022-07-07
Biosyntia–SEVERAL: investment, 202207 financing round Series B €11.5m led by new investor ECBF	2022-07-07
Aurobac Therapeutics–Boehringer: investment, 202207 launch of €40m joint venture Aurobac incl €30m from lead investor Boehringer Ingelheim	2022-07-06
BeiGene–InnoRNA: mRNA therapies, 202207– collab strategic r+d ww using InnoRNA LNP-based delivery technology with ww rights for BeiGene	2022-07-06
Boehringer–Evotec: investment, 202207 launch of €40m joint venture Aurobac incl €5m from co-investor Evotec	2022-07-06
Boehringer–Mérieux: investment, 202207 launch of €40m joint venture Aurobac incl €5m from co-investor bioMérieux	2022-07-06
Molzym–OTHER: investment, 202206 investment 2-digit €m from large single family office	2022-06-29
Green Generation–SEVERAL: investment, 202206 fund launched with €100m raised	2022-06-28
Verve Capital Partners–SEVERAL: investment, 202206 1st CHF45m closing of Verve Venture Fund I	2022-06-24
F-Star–Sino Biopharm: investment, 202206– acquisition $161m cash tender offer by invoX Pharma at $7.12/share ANNOUNCED	2022-06-23
Ningaloo Biosystems–North Rhine-Westphalia (govt): investment, 202206 pre-seed financing round incl investor NRW.Bank	2022-06-22
Ningaloo Biosystems–OTHER: investment, 202206 pre-seed financing round incl team of business angels	2022-06-22
Ningaloo Biosystems–SEVERAL: investment, 202206 pre-seed financing round with business angels + NRW.Bank	2022-06-22
SPT Labtech–EQT: investment, 202206– acquisition £650m of SPT Labtech by EQT IX Fund from Battery Ventures	2022-06-22
Carma Fund–EU (govt): investment, 202206 first closing totalling €47m of Carma Fund I incl investor EIF	2022-06-21
Carma Fund–Evotec: investment, 202206 first closing totalling €47m of Carma Fund I incl investor Evotec SE	2022-06-21
Carma Fund–Life Science-Stiftung: investment, 202206 first closing totalling €47m of Carma Fund I incl investor Ascenion GmbH	2022-06-21
Carma Fund–Orbit Fund Boutique: legal services, 202206 supply service legal advise on fund structure	2022-06-21
Carma Fund–SEVERAL: investment, 202206 first closing €47m of Carma Fund I with target size of €60m	2022-06-21
Carma Fund–Univ Frankfurt: investment, 202206 first closing totalling €47m of Carma Fund I incl investor Innovectis GmbH	2022-06-21
Novartis–Precision BioSciences: gene therapy, 202206– collab ww $50m upfront + $1.4b milestones + royalties using ARCUS platform to develop therapies	2022-06-21
Precision BioSciences–Novartis: investment, 202206 equity purchase $25m at $2.01/share in connection with collaboration	2022-06-21
Kranus Health–A Round Capital: investment, 202206 financing round Series A totalling >$6.5m incl existing + co-investor A Round Capital	2022-06-20
Kranus Health–High-Tech Gründerfonds: investment, 202206 financing round Series A totalling >$6.5m incl existing + co-investor HTGF	2022-06-20
Kranus Health–Karista: investment, 202206 financing round Series A totalling >$6.5m incl lead investor Karista	2022-06-20
Kranus Health–Peak Pride: investment, 202206 financing round Series A totalling >$6.5m incl co-investor Peak Pride	2022-06-20
Kranus Health–PERSON: investment, 202206 financing round Series A totalling >$6.5m incl co-investor Ehsan Khaljani	2022-06-20
Kranus Health–PERSON: investment, 202206 financing round Series A totalling >$6.5m incl co-investor Florian Brand	2022-06-20
Kranus Health–Saarbruecker21: investment, 202206 financing round Series A totalling >$6.5m incl co-investor business angel group Saarbruecker21	2022-06-20

1 2 3 ... 47 48 49

Picture [iito] Fighting Customers 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)